Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.

Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.